Speaker Profile
Ph.D., Professor of Empire Innovation, SUNY Binghamton University; Founder and CEO, Sostos Inc., Sostos Inc
Biography
Dr. Guo is the creator of CATOS-AI, which integrates multiomics and medical imaging to deliver patient-specific predictions of prognosis and treatment response in lung cancer — addressing a critical gap in precision oncology that existing molecular tests and imaging platforms cannot fill. Its lead product, CATOS-LU, is a 7-gene biomarker panel validated in 1,641 patients, including a randomized Phase III clinical trial, and classified by the FDA as a "Novel Technology" following Q-Submission review.
Dr. Guo has been awarded $46.3M in grant funding from NIH, NSF, and CDC as Principal Investigator/Project Director, has authored 76 peer-reviewed publications with 4,600+ citations, and holds 14 patents. She is a Fulbright U.S. Scholar in biomarker discovery. Sostos has been accepted into the NVIDIA Inception Program and NCI Investor Initiatives, and is advancing CATOS-AI through NSF SBIR Phase II with nine cancer center collaborators and active biopharma licensing discussions.
Talk
Transforming Cancer Care with AI-Powered Theranostics
Dr. Guo presents CATOS-LU, an AI-powered 7-gene assay validated in 1,600+ patients — including a Phase III trial — and introduces CATOS-AI, a broader precision oncology platform to optimize personalized treatment selection.
AI for Clinical Decision Support Systems Showcase:
Sostos Inc
Sostos is developing CATOS-AI, a precision oncology platform integrating multiomics and medical imaging to predict patient-specific prognosis and treatment response. Its lead product, CATOS-LU, is an AI-powered 7-gene lung cancer assay validated in 1,600+ patients, FDA-designated as a Novel Technology, with $9.8M in non-dilutive funding secured.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
